Announced Fri, 19 Jun · 08:24 IST
US FTC approves Aurobindo Pharma acquisition of Lannett business
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.4%1-day move
₹1447.30
prior close
₹1454.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+0.9+0.3+0.2+3.4+6.0+5.8+7.4+6.3+7.1+7.0+7.7——
Up moveDown movePending
AI summary
Aurobindo Pharma has received the necessary approvals from the US Federal Trade Commission (FTC) for its acquisition of Lannett business. This is a key regulatory clearance that brings the deal closer to completion. Lannett is a US-based generic pharmaceutical company. The intimation confirms that the antitrust review by the FTC has been satisfied, clearing a major hurdle for the transaction.
Likely market impact
Removes a key regulatory hurdle, moving the Lannett acquisition closer to closing and supporting Aurobindo's US generics expansion.